ライフサイエンスコーパス: IL-5R

1 n contrast to the mitogenic receptors IL-3R, IL-5R, GM-CSFR, which assemble as alphabeta heterodimers

2 ne receptor (interleukin-3 receptor [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating fac

3 High affinity receptor for IL-5 (IL-5R), a predominant eosinophil maturation factor, is c

4 Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosph

5 pha (IL-5Ralpha), a subunit of high-affinity IL-5R, on these cells.

6 Since message for the IL-5R alpha, IL-5R beta, and soluble IL-5R alpha chains was detected

7 op a multiplex assay, in which the IL-1R and IL-5R assays were carried out in the same well with each

8 the structural interactions between IL-5 and IL-5R and the functional consequences of such interactio

9 IL-5 and IL-5R drive allergic and inflammatory immune responses c

10 sted of the ectodomains of the GMR-alpha and IL-5R alpha, respectively, fused to the endodomain of IL

11 or with IL-2, increased both IL-5R alpha and IL-5R beta mRNA and decreased soluble IL-5R alpha mRNA.

12 tyrosine phosphorylation of JAK2 kinase and IL-5R beta-chain and inhibited IL-5 priming of leukotrie

13 inophils, IL-5R alpha gene transcription and IL-5R alpha mRNA metabolism can be regulated by mechanis

14 ion, IL-5-induced endocytosis, turnover, and IL-5R signaling were significantly impaired.

15 ld and clinical study data of anti-IL-5/anti-IL-5R therapies in severe eosinophilic asthma.

16 th IL-5 for binding to the native alpha beta IL-5R on human cells and inhibited IL-5-mediated recepto

17 eotide technology targeting the common betac IL-5R subunit is also being used therapeutically to inhi

18 or SAC, without or with IL-2, increased both IL-5R alpha and IL-5R beta mRNA and decreased soluble IL

19 is composed of an IL-5-binding alpha-chain (IL-5R alpha) and a signal-transducing beta-chain that is

20 example, interleukin-5 receptor alpha chain, IL-5R alpha).

21 their degradation, ubiquitination-deficient IL-5Rs accumulated on the cell surface and displayed blu

22 experiments that in human blood eosinophils, IL-5R alpha gene transcription and IL-5R alpha mRNA meta

23 mmunoreactive major basic protein, Siglec F, IL-5R alpha-chain, and transcripts encoding mouse eosino

24 e B cells, human B cells express message for IL-5R but can respond to IL-5 only if appropriately stim

25 ligand, with the maximum effect observed for IL-5R, consistent with the clinical phenotype of eosinop

26 A soluble form of the human IL-5R alpha-chain (IL-5Ra) that contains the extracellul

27 nding of the role of betac ubiquitination in IL-5R biology is currently lacking.

28 ry injury is associated with the activity of IL-5R-bearing cells.

29 onstrate that cytokine-induced inhibition of IL-5R alpha mRNA accumulation occurs at the level of IL-

30 pha mRNA accumulation occurs at the level of IL-5R alpha gene transcription, whereas enhanced accumul

31 Furthermore, increased levels of IL-5R alpha-chain were expressed by B-1a B cells in SMGs

32 ree cytokines on eosinophils and the loss of IL-5R on airway eosinophils, it is important to take IL-

33 rization reveals that the down-regulation of IL-5R alpha mRNA is specific to IL-3, IL-5, and GM-CSF;

34 was due to their differential regulation of IL-5R mRNA.

35 rget the eosinophilic inflammatory pathways (IL-5R and IL-5), namely mepolizumab, reslizumab, and ben

36 The IL-5 receptor (IL-5R) consists of an IL-5-specific alpha subunit that i

37 nd activation of the interleukin-5 receptor (IL-5R) or of the granulocyte-macrophage colony-stimulati

38 lly dependent on IL-5 and the IL-5 receptor (IL-5R), composed of a ligand binding alpha chain (IL-5Ra

39 st, benralizumab binds to the IL-5 receptor (IL-5R), preventing IL-5 from binding and leading to subs

40 tokines IL-5, IL-3, and GM-CSF down-regulate IL-5R alpha mRNA while up-regulating alpha-chain mRNAs f

41 for the IL-5R alpha, IL-5R beta, and soluble IL-5R alpha chains was detected in freshly isolated B ce

42 ha and IL-5R beta mRNA and decreased soluble IL-5R alpha mRNA.

43 As such, soluble IL-5R may be useful in treating diseases such as human a

44 re-clinical and clinical evidence supporting IL-5R as a therapeutic target.

45 mab (MEDI-563), has been developed to target IL-5R and attenuate eosinophilia through antibody-depend

46 Since message for the IL-5R alpha, IL-5R beta, and soluble IL-5R alpha chains

47 B cells with IL-4 induced expression of the IL-5R alpha-chain, while signaling through membrane Ig s

48 ugh membrane Ig stimulated expression of the IL-5R beta-chain.

49 d not mediate ECA activity by binding to the IL-5R or to CCR3.

50 Lyn kinase is physically associated with the IL-5R betac subunit in unstimulated cells.

51 interaction of the dimeric peptide with two IL-5R alpha chains represents a distinctive mechanism fo

52 Whereas ubiquitinated IL-5Rs internalized into trafficking endosomes for their